Navigation Links
Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Date:5/13/2009

sting treatments."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year. ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments. Circassia has a highly experienced management team with a proven track record in product development and commercialization. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visithttp://www.circassia.co.uk.

    Contacts:
    Steve Harris
    Rob Budge
    CEO RJB Communications
    Circassia
    Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
2. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
3. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
4. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
9. AFFiRiS Begins Development of a Parkinsons Vaccine
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22 2015 /CNW/ - The Taskforce representing Canada,s ... all the hard work that the Minister and Health Canada ... This program recognizes the needs of the thalidomide survivors, and ... a year, tax free, with annual adjustments for inflation. ... annual payments of $100,000 based on the severity of their ...
(Date:5/22/2015)... 22, 2015  Effective staffing of key marketing ... and success. Research and consulting ... provide pharmaceutical and biotech marketing managers with metrics ... that are being channeled into marketing operations of ... can utilize this report to benchmark their own ...
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
(Date:5/25/2015)... (PRWEB) May 25, 2015 24Hr HomeCare ... CEO, Tyner Brenneman-Slay, Co-Founder & COO, and Ryan Iwamoto, ... Young Entrepreneur Of The Year® 2015 Awards in Greater ... entrepreneurs who demonstrate excellence in innovation, financial performance, and ... are at the core of the ongoing success of ...
(Date:5/25/2015)... ProDrop Light Show allows users to now have ability ... click of a mouse. Users have full control over angle of ... Pro X. , ProDrop Light Show gives users 30 fully customizable ... more leaving infinite possibilities all within Final Cut Pro X. , ... users can apply their very own media files or text all ...
(Date:5/25/2015)... Dallas, TX (PRWEB) May 25, 2015 Decora ... renowned company ‘Leviton’ is now available on ‘The Hardware City.’ ... A user has to set a time and the related ... , When contacted a representative of the company said, “We ... ‘The Hardware City.’ Now customers can buy Countdown Timer Switch ...
(Date:5/24/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... which will allow them to take pressure measurements in ... bladder function. The doctor usually orders it if they ... overactive bladder (OAB). , Women’s Excellence in ... have problems with unwanted urinary leakage or problems with ...
(Date:5/24/2015)... Indianapolis, Indiana (PRWEB) May 24, 2015 ... network service provider announces Midwest Telecom of America, Inc. ... , According to Cory Childs, IFN Enterprise Sales ... to service providers. “IFN’s fiber transport provides MTA ... Operations Center to their Tier 1 Internet and voice ...
Breaking Medicine News(10 mins):Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2
... Man with Cerebral Palsy to Enjoy Time,with Wife and New ... were,the happy words marking the arrival of little Christopher Sokol. ... at the birth of,their first child, but they anticipated challenges ... became a lot easier for,them, thanks to a donated power ...
... Researchers say finding is ,good news, for postmenopausal ... News) -- Contrary to previous study results, the ... cause impairment of cognitive performance, a new study ... be superior to tamoxifen in preventing breast cancer ...
... University has discovered an entirely new signal path for a ... and growth of cancer cells. This discovery, published in ... an entirely new landscape for research on breast and prostate ... signals from various growth factors is critical for normal fetal ...
... 2, 2008) Today, University Health Network (UHN) ... have three 320-slice CT scanners, as Toronto Western ... most advanced Computer Tomography technology, the 320-slice CT ... help cancer specialists map tumours for treatment in ...
... , Compared to the 2003 guidelines, important new recommendations have ... setting up networks of hospitals with different levels of technology ... service , the selection of primary PCI vs ... both primary PCI and fibrinolytis , secondary prevention ...
... to date examining the impact of positron emission tomography ... recurrent colorectal cancer, researchers found that treatment plans were ... an article in the September issue of The ... conducted at four sites throughout Australia and comprised 191 ...
Cached Medicine News:Health News:The SCOOTER Store Donates Power Wheelchair, Giving New Parents Chance to Be an Active Family 2Health News:Breast Cancer Drug Not Tied to Cognitive Decline: Study 2Health News:New discovery about growth factor can be breakthrough for cancer research 2Health News:UHN becomes a world leader in medical imaging for stroke, cancer and cardiac patients 2Health News:UHN becomes a world leader in medical imaging for stroke, cancer and cardiac patients 3Health News:PET scans lead to treatment changes in majority of colorectal cancer patients 2
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Steroid-eluting, epicardial pacing leads...
Medicine Products: